Updated Efficacy & Safety Data from MacroGenics' TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients
Saturday, 14 September 2024, 23:59
MacroGenics Announces New Data
MacroGenics has announced promising results from the TAMARACK Phase 2 study, showcasing Vobra Duo's efficacy in treating mCRPC patients.
Key Findings
- Encouraging Antitumor Activity: The study noted a significant 6-month landmark rPFS rate.
- Overall Response Rate: Vobra Duo demonstrated an impressive overall response rate in mCRPC patients.
- Extended Treatment Duration: Patients remained on Vobra Duo for a median of 6 doses, with some reaching up to 12 doses.
Implications for Treatment
The implications of these findings highlight the potential of Vobra Duo as a promising therapeutic approach for patients with mCRPC. Ongoing studies will shed further light on its efficacy and safety.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.